 CAMBRIDGE, Mass., Dec. 10, 2020 GLOBE NEWSWIRE -- Spero Therapeutics, Inc. Nasdaq: SPRO, a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant MDR bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease NTM-PD in its dose-ranging Phase 2a clinical trial of SPR720, Speros oral antimicrobial agent in development for the treatment of NTM-PD. 